561 related articles for article (PubMed ID: 29157296)
1. Biomarkers for immunotherapy in bladder cancer: a moving target.
Aggen DH; Drake CG
J Immunother Cancer; 2017 Nov; 5(1):94. PubMed ID: 29157296
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
Lopez-Beltran A; Cimadamore A; Blanca A; Massari F; Vau N; Scarpelli M; Cheng L; Montironi R
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33401585
[TBL] [Abstract][Full Text] [Related]
3. Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice.
Nabar ND; Brandt MP; Thomas C; Tsaur I; Bartsch G; Jaeger W; Haferkamp A; Höfner T
Minerva Urol Nefrol; 2019 Jun; 71(3):205-216. PubMed ID: 30021426
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
5. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
Koshkin VS; Grivas P
Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
[TBL] [Abstract][Full Text] [Related]
6. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
Gwynn ME; DeRemer DL
Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813
[TBL] [Abstract][Full Text] [Related]
8. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD
J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors for urothelial carcinoma.
Kim HS; Seo HK
Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Bladder Cancer.
Konala VM; Adapa S; Aronow WS
Am J Ther; 2022 May-Jun 01; 29(3):e334-e337. PubMed ID: 30839322
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab for the treatment of urothelial carcinoma.
Alsharedi M; Srivastava R; Elmsherghi N
Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
14. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Bellmunt J; Powles T; Vogelzang NJ
Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
[TBL] [Abstract][Full Text] [Related]
15. Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review.
Kim TJ; Cho KS; Koo KC
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31940998
[TBL] [Abstract][Full Text] [Related]
16. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Einstein DJ; Sonpavde G
Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
Tafuri A; Smith DD; Cacciamani GE; Cole S; Shakir A; Sadeghi S; Vogelzang NJ; Quinn D; Gill PS; Gill IS
Clin Genitourin Cancer; 2020 Oct; 18(5):351-360.e3. PubMed ID: 32146152
[TBL] [Abstract][Full Text] [Related]
18. Avelumab for the treatment of urothelial cancer.
Rodriguez-Vida A; Bellmunt J
Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
[TBL] [Abstract][Full Text] [Related]
19. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.
Iacovelli R; Ciccarese C; Brunelli M; Battelli N; Buttigliero C; Caserta C; Buti S; Santini D; Carella C; Galli L; Verri E; Ermacora P; Merler S; Masini C; De Vivo R; Milesi L; Spina F; Rizzo M; Sperduti I; Fornarini G; Tortora G
Ann Oncol; 2022 Nov; 33(11):1179-1185. PubMed ID: 35926813
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]